Copy
Dear IMPRINT members,

We would like to remind you about the upcoming IMPRINT webinar on the impact of COVID-19 on neonates and the prevention of COVID-19 through vaccionation taking place on 11 March at 15:00-16:30 GMT.

We have invited Prof. Paul Heath, Professor of Paediatric Infectious Diseases at St George's, University of London, and Dr Chris Gale, Reader in Neonatal Medicine at Imperial College London. Prof. Heath will present the current status of COVID-19 vaccines, Dr Gale will discuss the impact of COVID-19 on the health of newborns. Please find more details on the presentations below.

The 20-minute presentations will each be followed by a Q&A session with speakers and audience that are moderated by our Network Directors Prof. Beate Kampmann from the London School of Hygiene & Tropical Medicine and Dr Chrissie Jones from the University of Southampton.
 
For registration, please follow this link: https://lshtm.zoom.us/webinar/register/WN_K7z7D9oSQZSST1CA-QNtTg

Presentations

COVID-19: Impact on the health of newborns
Dr Chris Gale, Imperial College London

Babies differ from older children with regard to their exposure to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). I will describe the incidence, characteristics, transmission, and outcomes of SARS-CoV-2 infection in neonates who received inpatient hospital care in the UK from a prospective population-based cohort study. Neonatal SARS-CoV-2 infection is uncommon in babies admitted to hospital. Infection with neonatal admission following birth to a mother with perinatal SARS-CoV-2 infection was unlikely, and possible vertical transmission rare, supporting international guidance to avoid separation of mother and baby.
 
COVID-19 vaccines: Current status
Prof. Paul Heath, St George’s, University of London

It was clear at an early stage that the rapid development, distribution and administration of a vaccine to the global population would be the most effective approach to suppress the SARS-CoV-2 pandemic. The first vaccine to be given to humans was the Moderna RNA vaccine which entered its Phase I trial an astonishing 63 days after sequence selection. This candidate represents a new vaccine platform technology and, although more traditional platforms are being employed, the use of new technologies, for which there are no previously licensed examples, is a particular feature of the COVID-19 vaccine field. A number of trials have recently reported efficacy data.
 
Best wishes,
Christoph

On behalf of the IMPRINT Management Board

Dr. Christoph Cyranski, IMPRINT network

LINQ management GmbH, Friedbergstr. 35, 14057 Berlin, Germany
Phone: +49 (0)30 300 96 447
http://www.linq-management.com/
http://www.imprint-network.co.uk/
Twitter: @IMPRINT_network
 
 

 







This email was sent to <<Email Address>>
why did I get this?    unsubscribe from this list    update subscription preferences
LINQ management GmbH · Trendelenburgstr. 14A · Berlin 14057 · Germany

Email Marketing Powered by Mailchimp